$5.17
8.82% yesterday
Nasdaq, Sep 22, 10:16 pm CET
ISIN
US03843E1047
Symbol
AQST

Aquestive Therapeutics, Inc. Stock price

$5.17
+1.19 29.90% 1M
+1.92 59.08% 6M
+1.61 45.22% YTD
+0.29 5.94% 1Y
+4.10 383.18% 3Y
-3.31 39.03% 5Y
-10.88 67.79% 10Y
-10.88 67.79% 20Y
Nasdaq, Closing price Mon, Sep 22 2025
-0.50 8.82%
ISIN
US03843E1047
Symbol
AQST
Industry

Key metrics

Basic
Market capitalization
$625.4m
Enterprise Value
$599.9m
Net debt
positive
Cash
$60.5m
Shares outstanding
99.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
14.2 | 13.6
EV/Sales
13.6 | 13.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-59.3%
Return on Equity
73.4%
ROCE
-74.6%
ROIC
-280.5%
Debt/Equity
-0.5
Financials (TTM | estimate)
Revenue
$44.1m | $45.8m
EBITDA
$-52.0m | $-52.7m
EBIT
$-52.6m | $-55.4m
Net Income
$-65.0m | $-72.0m
Free Cash Flow
$-50.0m
Growth (TTM | estimate)
Revenue
-24.4% | -20.4%
EBITDA
-270.2% | -75.2%
EBIT
-246.2% | -80.0%
Net Income
-152.9% | -63.0%
Free Cash Flow
-100.8%
Margin (TTM | estimate)
Gross
61.1%
EBITDA
-117.9% | -114.8%
EBIT
-119.2%
Net
-147.4% | -156.9%
Free Cash Flow
-113.3%
More
EPS
$-0.7
FCF per Share
$-0.5
Short interest
8.8%
Employees
142
Rev per Employee
$410.0k
Show more

Is Aquestive Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Aquestive Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Aquestive Therapeutics, Inc. forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Aquestive Therapeutics, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Aquestive Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
44 44
24% 24%
100%
- Direct Costs 17 17
7% 7%
39%
27 27
33% 33%
61%
- Selling and Administrative Expenses 60 60
54% 54%
136%
- Research and Development Expense 20 20
21% 21%
45%
-52 -52
270% 270%
-118%
- Depreciation and Amortization 0.59 0.59
49% 49%
1%
EBIT (Operating Income) EBIT -53 -53
246% 246%
-119%
Net Profit -65 -65
153% 153%
-147%

In millions USD.

Don't miss a Thing! We will send you all news about Aquestive Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aquestive Therapeutics, Inc. Stock News

Positive
Seeking Alpha
18 days ago
Aquestive Therapeutics's Anaphylm could be the first FDA-approved, non-invasive, orally delivered epinephrine for anaphylaxis, with a PDUFA date set for January 2026. FDA's decision not to convene an advisory committee is a positive signal, and clinical data seems to strongly support Anaphylm's safety and efficacy. If approved, Anaphylm could capture significant market share, potentially drivin...
Neutral
GlobeNewsWire
about one month ago
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at an offering price of $4...
Neutral
GlobeNewsWire
about one month ago
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP (“RTW”), subject to Uni...
More Aquestive Therapeutics, Inc. News

Company Profile

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.

Head office United States
CEO Daniel Barber
Employees 142
Founded 2004
Website aquestive.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today